Jazz’s Zepzelca Shored Up By Small-Cell Lung Cancer Success
The combination results with Tecentriq bolster the case for Jazz’s drug, but it will still face competition from Amgen’s Imdeltra and others in the hard-to-treat cancer.
The combination results with Tecentriq bolster the case for Jazz’s drug, but it will still face competition from Amgen’s Imdeltra and others in the hard-to-treat cancer.